Merck KGaA

OTC Pink - Current Information:MKKGYUnited States

Nov 14, 2024

Show headlines and story abstract

• DJ Merck KGaA's Sales Target Dragged by Muted China Outlook -- Market Talk, from 6:15AM ET on Thursday Nov 14, 2024 by Dow Jones

  6:15AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: MKKGY
  
  1115 GMT - Merck KGaA expects its 2024 sales target to come in at the lower end of its guided range partly due to weaker China. Performance in China is bottoming out, with growth expectations lagging previous hopes, Chief Financial Officer Helene von Roeder says in a call with reporters. The German life-sciences and chemical group had already lowered its medium-term sales growth forecasts for its life-science and healthcare businesses in October due to a muted outlook in China. Shares fall 1.8% to EUR148.80.(helena.smolak@wsj.com)
  

• DJ Merck KGaA's Life-Science Sales Recovery Is Encouraging -- Market Talk, from 5:45AM ET on Thursday Nov 14, 2024 by Dow Jones

  5:45AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: MKKGY
  
  1044 GMT - Merck KGaA's sales recovery at its life science segment is encouraging, Morgan Stanley analysts say in a note. Although the German life-sciences and chemical group now guides for full-year sales at the bottom end of the forecast range, its life-science segment returned to sales growth in the quarter, they say. The segment was boosted by inventory destocking gradually coming to an end, and a further recovery in order intake compared with last quarter, the analysts say. Shares fall 1.8% to EUR148.80. (helena.smolak@wsj.com)
  

• DJ Merck KGaA's Electronics Division Disappointed -- Market Talk, from 4:26AM ET on Thursday Nov 14, 2024 by Dow Jones

  4:26AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: MKKGY
  
  0925 GMT - Merck KGaA's electronics division's sales failed to live up to investor expectations in the third quarter, Equita analysts say in a research note. Sales at the business grew 2.4% on an organic basis, coming below consensus expectations of 6.5% growth and below Equita's estimate of 5.7% growth, the analysts say. Weakness in the display business and a more gradual than expected recovery in the semiconductor business hurt the division, Equita adds. Life science grew 2.1%, confirming that the division is on track to recover, although the figure is slightly below consensus, Equita says. Weaker revenue was offset by a stronger-than-expected margin, it adds. (maitane.sardon@wsj.com)
  

• DJ Merck KGaA Earnings Growth Beats Expectations -- Update, from 2:54AM ET on Thursday Nov 14, 2024 by Dow Jones

  2:54AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: MKKGY
  
  By Helena Smolak
  
  Merck KGaA reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in the life-sciences segment, but said full-year sales would come in at the bottom end of the forecast range.
  

• *DJ Analysts Saw Merck KGaA 3Q Net Sales at EUR5.33B, from 1:00AM ET on Thursday Nov 14, 2024 by Dow Jones

  1:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: MKKGY
  By Helena Smolak Germany's Merck KGaA expects annual sales to be at the lower half of its outlook range after third-quarter sales missed expectations. The life-sciences and chemical group said Thursday that it now expects 2024 net sales in the lower half of its previously expected range of 20.7 billion to 22.1 billion euros ($21.87 billion-$23.35 billion). Net sales for the quarter rose 1.8% to 5.27 billion euros but missed analysts' expectations of 5.33 billion euros, according to consensus estimates provided by the company. Earnings before interest taxes depreciation and amortization before one-time items grew 12% to 1.62 billion euros, outperforming analysts' estimates of 1.55 billion euros, according to the company-compiled consensus. The company's adjusted earnings per share stood at 2.30 euros compared with 2.07 euros in the prior-year period. Merck made an after-tax profit of 812 million euros compared with 740 million in the same period last year. The company stuck to its full-year earnings guidance, forecasting Ebitda excluding one-time items around the mid-point of its previously guided 5.8 billion to 6.4 billion euros range. It also expects adjusted EPS at around the mid-point of 8.20 to 9.30 euros. Write to Helena Smolak at helena.smolak@wsj.com (END) Dow Jones Newswires November 14, 2024 01:11 ET (06:11 GMT)